Evotec SE ADR (EVO)vsZoetis Inc (ZTS)
EVO
Evotec SE ADR
$2.52
+7.69%
HEALTHCARE · Cap: $902.78M
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1152% more annual revenue ($9.47B vs $756.33M). ZTS leads profitability with a 28.2% profit margin vs -21.0%. EVO appears more attractively valued with a PEG of 1.42. ZTS earns a higher WallStSmart Score of 64/100 (C+).
EVO
Hold38
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVO.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18.0% — below average capital efficiency
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.12 — expect wider price swings.
ZTS is growing revenue faster at 3.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 38/100), backed by strong 28.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a leading global biotechnology company based in Hamburg, Germany, renowned for its comprehensive drug discovery and development solutions tailored for the pharmaceutical and biotech industries. The firm utilizes a collaborative model, partnering with various stakeholders—ranging from established pharmaceutical companies to innovative academic institutions—to propel the advancement of therapeutic programs across numerous modalities, including small molecules, biologics, and cell therapies. With a robust pipeline of projects and a steadfast focus on enhancing patient outcomes, Evotec is well-positioned to capitalize on emerging opportunities in the biopharmaceutical sector, solidifying its pivotal role in driving healthcare innovation.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?